INSPRA Rx

Select the drug indication to add to your list

INSPRA

CHF and arrhythmias
Hypertension
Only 4 drugs may be compared at once

Generic Name and Formulations:

Eplerenone 25mg, 50mg; tabs.

Company:

Pfizer Inc.

Select therapeutic use:

Indications for INSPRA:

To improve survival of stable patients with left ventricular systolic dysfunction (ejection fraction ≤40%) and clinical evidence of CHF after acute MI.

Adult:

Initially 25mg once daily; titrate within 4 weeks to 50mg once daily. Adjust based on serum K+ (see full labeling). Concomitant moderate CYP3A inhibitors (eg, erythromycin, verapamil, saquinavir, fluconazole): max 25mg daily.

Children:

Not recommended.

Contraindications:

Hyperkalemia (serum K+ >5.5mEq/L) at initiation, severe renal impairment (CrCl ≤30mL/min), or concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir).

Warnings/Precautions:

Renal impairment, proteinuria, diabetes: increased risk of hyperkalemia. Monitor serum K+ at baseline, within 1st week, at 1 month after starting and after dose adjustment, then periodically. Check serum K+ and serum creatinine within 3–7 days after initiating a moderate CYP3A inhhibitors, ACEIs, ARBs, or NSAIDs. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

CYP3A inhibitors (see Contraindications and Dose). NSAIDs may antagonize antihypertensive effects. Angiotensin II receptor blockers, ACEIs, and NSAIDs increase hyperkalemia risk. Monitor lithium.

Pharmacological Class:

Aldosterone receptor blocker (mineralocorticoid-selective).

Adverse Reactions:

Hyperkalemia, increased creatinine.

Generic Availability:

NO

How Supplied:

Tabs—30, 90

INSPRA 50mg tablets (Qty:30)

appx. price $328.00

Indications for INSPRA:

Hypertension.

Adult:

Initially 50mg once daily; may increase after 4 weeks to max 50mg twice daily. Concomitant moderate CYP3A inhibitors (eg, erythromycin, verapamil, saquinavir, fluconazole): initially 25mg once daily; max 25mg twice daily.

Children:

Not recommended.

Contraindications:

Hyperkalemia (serum K+ >5.5mEq/L) at initiation, severe renal impairment (CrCl ≤30mL/min), or concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir). Type 2 diabetes with microalbuminuria, CrCl<50mL/min, serum creatinine >2mg/dL (males), >1.8mg/dL (females), or concomitant K+ supplements or K+ sparing diuretics.

Warnings/Precautions:

Renal impairment, proteinuria, diabetes: increased risk of hyperkalemia. Monitor serum K+ at baseline, within 1st week, at 1 month after starting and after dose adjustment, then periodically. Check serum K+ and serum creatinine within 3–7 days after initiating a moderate CYP3A inhhibitors, ACEIs, ARBs, or NSAIDs. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

CYP3A inhibitors (see Contraindications and Dose). NSAIDs may antagonize antihypertensive effects. Angiotensin II receptor blockers, ACEIs, and NSAIDs increase hyperkalemia risk. Monitor lithium.

Pharmacological Class:

Aldosterone receptor blocker (mineralocorticoid-selective).

Adverse Reactions:

Hyperkalemia, increased creatinine.

Generic Availability:

NO

How Supplied:

Tabs—30, 90

INSPRA 50mg tablets (Qty:30)

appx. price $328.00